News

Molecular Partners Confirms Ultra-Potent Inhibition of SARS-CoV-2 Live Virus by Anti-COVID-19 DARPin® Candidates

Zurich-Schlieren, Switzerland, May 7, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced completion of in vitro potency assessments of its DARPin® candidates targeting live, replicating coronavirus SARS-CoV-2. These candidates show extremely robust antiviral activity,...

read more

Interim Management Statement Q1 2020: Continued Progress on Abicipar, Sharpened Focus on Pipeline Activities

Zurich-Schlieren, Switzerland, May 7, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2020. “We have responded to the current global pandemic in three ways: ensuring the...

read more

Securecell Webinar: How to Digitalize Bioprocess Development

Join us for a webinar on May 18, 2020 at 10:00 AM CEST. Register now! Digitalization of bioprocess development - challenges of digitization and opportunities arising from central data management and harmonized workflows. Learn about: - Lab equipment communication - Disparate data sources in bioprocess development - Lucullus® concepts & workflows ...including a live Q&A session with...

read more

Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi-Target Binding of DARPin® Proteins to Neutralize SARS-CoV-2 Virus

Zurich-Schlieren, Switzerland, April 20, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, has identified multiple potent monospecific DARPin® proteins which neutralize samples of the SARS-CoV-2 virus. The company has engineered these proteins into trispecific antiviral...

read more

Center for Laboratory Medicine St. Gallen is the first laboratory to offer Proclarix® from Proteomedix

Schlieren and St. Gallen, Switzerland, April 2, 2020. The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer diagnosis, is made available by the Center for Laboratory Medicine St. Gallen (Zentrum für Labormedizin St. Gallen, ZLM). ”Proclarix is...

read more